Entry Detail

General Information

Database ID: LDA0021999
Species: Homo sapiens
Confidence Score: 0.548294
Contents: >> ncRNA Information
>> ncRNA Association Statistics
>> Disease Information
>> Disease Association Statistics
>> Evidence Support
>> Reference
Causality: Unknown
Clinical Significance: Yes

 


ncRNA Information

Reference Genome Note: GRCh38 for human lncRNAs; GRCm39 for mouse lncRNAs; mRatBN7.2 for rat lncRNAs; hg19 for human circRNAs; mm9 for mouse circRNAs.

ncRNA Symbol:AOX2P
Full Name:aldehyde oxidase 2, pseudogene
Category:LncRNA
Species:Homo sapiens
Synonyms:AOH2|AOX2|AOX3L1
Chromosome:2
Strand:+
Coordinate:
Start Site(bp):200738639End Site(bp):200791636
External Links:
Ensembl ID:ENSG00000243478
Ensembl Transcript ID:N/A
Entrez Gene:344454.0
NONCODE ID:N/A
RefSeq Accession:N/A

 

ncRNA Association Statistics

Total Associated Disease Number:2   
More Information
Causal Disease Number:0
Network:
Top Causal Diseases:
More Information

 

 

Disease Information

 Disease OntologyMeSH
Disease ID:DOID:9119D015470
Disease Name:acute myeloid leukemiaLeukemia, Myeloid, Acute
Category:Disease OntologyMeSH
Type:Neoplasms
Define:A myeloid leukemia that is characterized by the rapid growth of abnormal white blood cells that accumulate in the bone marrow and interfere with the production of normal blood cells.Clonal expansion of myeloid blasts in bone marrow, blood, and other tissue. Myeloid leukemias develop from changes in cells that normally produce NEUTROPHILS; BASOPHILS; EOSINOPHILS; and MONOCYTES.
Alias:AML - acute Myeloid Leukemia//Leukemia, Myelocytic, acute//acute myeloblastic leukaemia//acute myeloblastic leukemia//acute myelogenous leukaemia//acute myelogenous leukemia//acute myeloid leukaemiaLeukemia, Myeloid, Acute//Acute Myeloid Leukemia//Acute Myeloid Leukemias//Leukemias, Acute Myeloid//Myeloid Leukemias, Acute//ANLL//Leukemia, Acute Myelogenous//Leukemia, Acute Myeloid//Leukemia, Myeloblastic, Acute//Leukemia, Myelocytic, Acute//Leukemia, Myelogenous, Acute//Leukemia, Nonlymphoblastic, Acute//Leukemia, Nonlymphocytic, Acute//Myeloblastic Leukemia, Acute//Acute Myeloblastic Leukemia//Acute Myeloblastic Leukemias//Leukemia, Acute Myeloblastic//Leukemias, Acute Myeloblastic//Myeloblastic Leukemias, Acute//Myelocytic Leukemia, Acute//Acute Myelocytic Leukemia//Acute Myelocytic Leukemias//Leukemia, Acute Myelocytic//Leukemias, Acute Myelocytic//Myelocytic Leukemias, Acute//Myelogenous Leukemia, Acute//Myeloid Leukemia, Acute//Nonlymphoblastic Leukemia, Acute//Acute Nonlymphoblastic Leukemia//Acute Nonlymphoblastic Leukemias//Leukemia, Acute Nonlymphoblastic//Leukemias, Acute Nonlymphoblastic//Nonlymphoblastic Leukemias, Acute//Nonlymphocytic Leukemia, Acute//Acute Nonlymphocytic Leukemia//Acute Nonlymphocytic Leukemias//Leukemia, Acute Nonlymphocytic//Leukemias, Acute Nonlymphocytic//Nonlymphocytic Leukemias, Acute//Acute Myelogenous Leukemia//Acute Myelogenous Leukemias//Leukemias, Acute Myelogenous//Myelogenous Leukemias, Acute//Myeloid Leukemia, Acute, M1//Leukemia, Myeloid, Acute, M1//Acute Myeloid Leukemia without Maturation//Leukemia, Myeloid, Acute, M2//Myeloid Leukemia, Acute, M2//Acute Myeloid Leukemia with Maturation

 

Disease Association Statistics

Total Associated ncRNA Number:196   
More Information
Causal ncRNA Number:138
Network:
Top Causal ncRNAs:
SNHG1  (Score: 1)
SNHG1  (Score: 1)
NEAT1  (Score: 1)
NEAT1  (Score: 1)
TUG1  (Score: 0.999998)
TUG1  (Score: 0.999998)
MVIH  (Score: 0.999893)
SNHG5  (Score: 0.999893)
CDKN2B-AS1  (Score: 0.999893)
SNHG5  (Score: 0.999893)
More Information

 

Evidence Support

Strong Evidence:
Weak Evidence:Bioinformatics Analysis

 

Reference

[1] PubMed ID:34129278
Disease Name:Leukemia, Myeloid, Acute
Sample:blood
Dysfunction Pattern:Expression(highly expressed)
Validated Method:Bioinformatics Analysis
Description:Upregulated CRNDE expression was independently associated with lower complete remission (CR) rates in the whole cohort of AML (P < .001). AOX2P overexpression was identified as an independent adverse prognostic marker for CR in the CN-AML (P = .009) and non-t (15;17) AML (P < .001) subgroups. Patients with high CRNDE expression had a significantly shorter event-free survival (EFS, whole cohort of AML: P = .017; CN-AML: P = .001; non-t (15;17) AML: P = .006) and inferior overall survival (OS, whole cohort of AML: P = .002; t(15;17) AML: P = .001) than those with low CRNDE expression. EFS and OS did not differ significantly between patients with high AOX2P expression and those with low expression.
Causality:No
Causal Description:
Clinical-realted Application:Upregulated CRNDE expression was independently associated with lower complete remission (CR) rates in the whole cohort of AML (P < .001). AOX2P overexpression was identified as an independent adverse prognostic marker for CR in the CN-AML (P = .009) and non-t (15;17) AML (P < .001) subgroups. Patients with high CRNDE expression had a significantly shorter event-free survival (EFS, whole cohort of AML: P = .017; CN-AML: P = .001; non-t (15;17) AML: P = .006) and inferior overall survival (OS, whole cohort of AML: P = .002; t(15;17) AML: P = .001) than those with low CRNDE expression. EFS and OS did not differ significantly between patients with high AOX2P expression and those with low expression.